Dr Zane Kaplan
Learn more about Monash Health’s Haematology team.
Dr Zane Kaplan
BMedSc(Hons), MBBS (Hons), FRACP, FRCPA, PhD
Dr Zane Kaplan is clinical and laboratory haematologist as well as a molecular pathologist at Monash Health. He is also the head of the state Haemoglobinopathy and Haemophilia reference laboratory, providing molecular diagnostics including Chorionic Villus Sample (CVS) testing for the state of Victoria and Tasmania. Dr Kaplan is the head of the haemoglobinopathy service and the medical lead of the Medical Infusion Unit at Monash Health.
Dr Kaplan is a senior lecturer for the Department of Haematology in the School of Clinical Sciences Monash University. His laboratory and clinical focus is on the molecular diagnosis and management of thalassaemia and sickle cell disease, as well as the development of novel therapeutic strategies in these diseases. Additionally, he has research interest in haemostasis and thrombosis having undertaken a PhD in the field at Australian Centre for Blood Diseases at the Alfred Hospital. He continues to be actively involved in research being as PhD supervisor and researcher in both clinical trials as well as basic scientific research.
In the last 5 years Dr Kaplan has co-authored multiple publication in high-ranking journals including the New England Journal of Medicine, Lancet Haematology, Blood and Blood Advances. Dr Kaplan is actively involved in medical student as well as post graduate teaching and is a Royal College of Pathologists of Australasia examiner in haematology and molecular pathology.
Key recent publications (last 5 years)
- Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia. Taher A, Diamantidis MD, Kattamis A, Aydinok Y, Kaplan ZS, Dibble A, Dorow S, Doherty S, Mathews J, Jung S, Goldberg YP, Tami J, Bhanot S, Schneider E, Monia BP, Barrett TD. Blood Adv. 2026 Jun 4:bloodadvances.2026019799. Online ahead of print.
- Obstetric and Gynaecologic Considerations in Inherited Bleeding Disorders. Connell NT, Davies J, Abdul-Kadir R, Kaplan Z. Haemophilia. 2026 Apr 16. doi: 10.1111/hae.70267.
- Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, Ware RE, Abboud MR, Abraham A, Ambrose EE, Andemariam B, Colah R, Colombatti R, Conran N, Costa FF, Cronin RM, de Montalembert M, Elion J, Esrick E, Greenway AL, Idris IM, Issom DZ, Jain D, Jordan LC, Kaplan ZS, King AA, Lloyd-Puryear M, Oppong SA, Sharma A, Sung L, Tshilolo L, Wilkie DJ, Ohene-Frempong K. Lancet Haematol. 2023 Aug;10(8): e633-e686.
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. N Engl J Med. 2022 Apr 14;386(15):1421-1431.
- Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major. Zargari A, Wu S, Greenway A, Cheng K, Kaplan Z. Vox Sang. 2022 May;117(5):733-737.